Â鶹ӳ»­

Â鶹ӳ»­ MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a novel HER2-targeted bispecific antibody for several types of cancers, an immunotherapy and PARP-inhibitor combination that may benefit specific tumor molecular subtypes, a comprehensive look at the efficacy of eligibility criteria...

A new preclinical study from researchers at Â鶹ӳ»­ MD Anderson Cancer Center and the University of California San Francisco (UCSF) has discovered the underlying cause of gender differences in immunotherapy-associated myocarditis after immune checkpoint inhibitor (ICI) treatment. Their findings point to possible treatment strategies for this side effect, which disproportionately affects female patients.

The...